With almost half of all Nigerians living below the poverty line and facing the dual burden of a high incidence of both infectious and non-communicable diseases (NCDs), Nigeria’s under-funded public health system is under significant pressure. Accordingly, international aid organisations and the private sector have a major role to play in alleviating the burden on the state, and there is a strong need for stakeholders to work together to ensure that reliable and affordable health care reaches all segments of society. While significant progress has been made in the reduction of life-threatening infectious diseases and performance on key health indices is improving, there is still a long way to go to meet the UN’s Millennium Development Goals (MDG), an objective that is incorporated into Vision 20:2020, the country’s long-term economic development strategy. There are also hurdles to overcome in ensuring that every Nigerian, irrespective of geography and income, has access to basic health services. The Ministry of Health has proposed ambitious initiatives that could dramatically improve the provision of health care at all levels; execution and delivery will be dependent on key legislative bills being passed, the requisite funding being mobilised and the direction of the new administration.

This chapter contains an interview with Colin Cummings, Chairman and CEO, Swiss Pharma Nigeria.

Cover of The Report: Nigeria 2015

The Report

This chapter is from the Nigeria 2015 report. Explore other chapters from this report.

Interviews & Viewpoints

Sketch of  OBG talks to Colin Cummings, Chairman and CEO, Swiss Pharma Nigeria
Colin Cummings, Chairman and CEO, Swiss Pharma Nigeria: Interview

Covid-19 Economic Impact Assessments

Stay updated on how some of the world’s most promising markets are being affected by the Covid-19 pandemic, and what actions governments and private businesses are taking to mitigate challenges and ensure their long-term growth story continues.

Register now and also receive a complimentary 2-month licence to the OBG Research Terminal.

Register Here×

Product successfully added to shopping cart